Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 5/20 | 0.56 |
| ▸ | HRH1 | P35367 | 5/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | MIF | P14174 | 1/20 | 0.45 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL10389261 | 1.00 | HTR2A (0.56) | HTR2AHRH1LMNATDP1TAAR1 | |
| SCHEMBL54346 | 0.97 | HTR2A (0.59) | HTR2AHRH1LMNATDP1TAAR1 | |
| Methane SCHEMBL28250836 | 0.94 | HTR2A (0.56) | HTR2AHRH1LMNATDP1TAAR1 | |
| Phosphine SCHEMBL28948486 | 0.94 | HTR2A (0.56) | HTR2AHRH1LMNATDP1TAAR1 | |
| SCHEMBL12506256 | 0.94 | HTR2A (0.56) | HTR2AHRH1LMNATDP1TAAR1 | |
| SCHEMBL29268835 | 0.94 | HTR2A (0.56) | HTR2AHRH1LMNATDP1TAAR1 | |
| Dimethylamine SCHEMBL8170436 | 0.89 | HTR2A (0.54) | HTR2AHRH1LMNATDP1TAAR1 | |
| Trimethylammonium SCHEMBL27512056 | 0.89 | HTR2A (0.65) | HTR2AHRH1LMNATDP1TAAR1 | |
| SCHEMBL20721735 | 0.87 | HTR2A (0.50) | HTR2AHRH1LMNATDP1TAAR1 | |
| P-Xylene SCHEMBL20836570 | 0.87 | HTR2A (0.50) | HTR2AHRH1LMNATDP1TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102575004-B | Polyamide compound and epoxy resin composition containing same | ADEKA CORP | 2014-06-25 | — | — | CN | disclosed |
| US-20060142594-A1 | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases | MUELLER ALAN L | 2006-06-29 | — | — | US | disclosed |
| CN-1769274-A | Pyrazinone protease inhibitors | DIMENSIONAL PHARM INC (US) | 2006-05-10 | — | — | CN | disclosed |
| EP-1617790-A1 | DRUG-LOADED MEDICAL DEVICE | Boston Scientific Scimed, Inc. (US) | 2006-01-25 | — | — | EP | disclosed |
| CN-1224629-C | Pyrazinone protease inhibitors | DIMENSIONAL PHARM INC (US) | 2005-10-26 | — | — | CN | disclosed |
| WO-2004096096-A1 | DRUG-LOADED MEDICAL DEVICE | SCIMED LIFE SYSTEMS, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| US-6750244-B2 | NERVOUS SYSTEM DISORDERS | NPS PHARMACEUTICALS, INC. | 2004-06-15 | — | — | US | disclosed |
| US-20040092747-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | BENDER STEVEN LEE (US) | 2004-05-13 | — | — | US | disclosed |
| US-6635641-B2 | For treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, psoriasis | AGOURON PHARMACEUTICALS, INC. | 2003-10-21 | — | — | US | disclosed |
| US-20020103203-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2002-08-01 | — | — | US | disclosed |
| CN-1305492-A | Pyrazinone protease inhibitors | DIMENSIONAL PHARM INC (US) | 2001-07-25 | — | — | CN | disclosed |
| US-6211245-B1 | DRUGS FOR CONTROLLING CALCIUM MODULATORS | NPS PHARMACEUTICALS, INC. | 2001-04-03 | — | — | US | disclosed |
| US-6017965-A | TREATING STROKE, HEAD TRAUMA, SPINAL CORD INJURY, SPINAL CORD ISCHEMIA, ISCHEMIA- OR HYPOXIA-INDUCED NERVE CELL DAMAGE, EPILEPSY, ANXIETY, NEUROPSYCHIATRIC OR COGNITIVE DEFICITS DUE TO ISCHEMIA OR HYPOXIA | NPS PHARMACEUTICALS, INC. (US) | 2000-01-25 | — | — | US | disclosed |
| EP-0801083-A2 | Improved functionalized resin for chemical synthesis | PFIZER INC. (US) | 1997-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092747-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | BRAF, CNKSR1, UACA | HTR2A 4238/4885HRH1 1280/4885LMNA 4001/4885 |
| US-20060142594-A1 | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases | NCS1, ATP2A1, CACNA1D | HTR2A 390/4885HRH1 403/4885LMNA 723/4885 |
| US-20020103203-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | BRAF, CNKSR1, UACA | HTR2A 4238/4885HRH1 1280/4885LMNA 4001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.